» Articles » PMID: 18590745

Clozapine Interacts with the Glycine Site of the NMDA Receptor: Electrophysiological Studies of Dopamine Neurons in the Rat Ventral Tegmental Area

Overview
Journal Life Sci
Publisher Elsevier
Date 2008 Jul 2
PMID 18590745
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Clozapine has a remarkable efficacy in treatment-resistant schizophrenia and is one of the most effective antipsychotic drugs used today. The clinical effects of clozapine are suggested to be related to a unique interaction with a variety of receptor systems, including the glutamatergic receptors. Kynurenic acid (KYNA) is an endogenous blocker of alpha7 nicotinic receptors and a glutamate-receptor antagonist, preferentially blocking N-methyl-D-aspartate (NMDA) receptors. In the present in vivo electrophysiological study, changes in endogenous concentration of brain KYNA were utilized to analyze an interaction between clozapine and the glycine site of NMDA receptors. In control rats intravenously administered clozapine (0.078-10 mg/kg) increased the firing rate and the burst firing activity of dopamine (DA) neurons in the ventral tegmental area (VTA). Pretreatment with indomethacin (50 mg/kg, i.p., 1-3.5 h), a cyclooxygenase (COX)-inhibitor with a preferential selectivity for COX-1, which produced a significant elevation in brain KYNA levels, reversed the excitatory action of clozapine into an inhibitory response. In contrast, pretreatment with the COX-2 selective inhibitor parecoxib (25 mg/kg, i.v., 1-1.5 h) decreased brain KYNA formation and furthermore, clearly potentiated the excitatory effect of clozapine. Our results show that endogenous levels of brain KYNA are of importance for the response of clozapine on VTA DA neurons. On the basis of the present data we propose that clozapine is able to interact with glutamatergic mechanisms, via actions at the NMDA/glycine receptor.

Citing Articles

The dopaminergic system mediates the lateral habenula-induced autonomic cardiovascular responses.

Sato Y, Matsumoto M, Koganezawa T Front Physiol. 2024; 15:1496726.

PMID: 39640253 PMC: 11617519. DOI: 10.3389/fphys.2024.1496726.


Dysfunction of the NMDA Receptor in the Pathophysiology of Schizophrenia and/or the Pathomechanisms of Treatment-Resistant Schizophrenia.

Okubo R, Okada M, Motomura E Biomolecules. 2024; 14(9).

PMID: 39334894 PMC: 11430065. DOI: 10.3390/biom14091128.


Multiple serum anti-glutamate receptor antibody levels in clozapine-treated/naïve patients with treatment-resistant schizophrenia.

He J, Li J, Wei Y, He Z, Liu J, Yuan N BMC Psychiatry. 2024; 24(1):248.

PMID: 38566016 PMC: 10985978. DOI: 10.1186/s12888-024-05689-0.


Canonical and Non-Canonical Antipsychotics' Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia.

de Bartolomeis A, Ciccarelli M, De Simone G, Mazza B, Barone A, Vellucci L Int J Mol Sci. 2023; 24(6).

PMID: 36983018 PMC: 10051989. DOI: 10.3390/ijms24065945.


Targeting D-Amino Acid Oxidase (DAAO) for the Treatment of Schizophrenia: Rationale and Current Status of Research.

Kuo C, Lin C, Lane H CNS Drugs. 2022; 36(11):1143-1153.

PMID: 36194364 DOI: 10.1007/s40263-022-00959-5.